^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
Excerpt:
...- At least 18 years old with histologically- or cytologically-confirmed diagnosis of adenocarcinoma Stage IV NSCLC with a positive mutational status for the KRAS, NRAS, BRAF, or MEK1 gene....
Trial ID:
Source:
Title:
A Study to Test a New Drug (GSK1120212) to Treat Lung Cancer
Excerpt:
...Histologically- or cytologically-confirmed diagnosis of adenocarcinoma Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLC with a positive mutational status for the KRAS, NRAS, BRAF, or MEK1 gene (performed in a CLIA-certified laboratory or equivalent). ...
Trial ID:
Less C2 evidence
Source:
Title:
Characteristics of Lung Cancers Harboring NRAS Mutations
Excerpt:
To identify potential therapies for patients with NRAS mutant tumors, we tested the sensitivity of 6 NRAS mutant NSCLC cell lines (Table S3) against a variety of kinase inhibitors in in vitro cell growth inhibition assays (Fig. 2A). None of the lines were sensitive (with lower than 1 micromolar IC50s) to the EGFR TKI, erlotinib, the ALK/MET/RON/ROS1 inhibitor, crizotinib, or the IGF-1R inhibitor, linsitinib. By contrast, 5 of 6 lines were sensitive to two different MEK inhibitors, selumetinib and trametinib.
DOI:
10.1158/1078-0432.CCR-12-3173
